TGFβ-Regulated Progression of Thrombocytopenia Reduced in Patients with Advanced Myelofibrosis Receiving AVID200 Therapy

Conference Correspondent —December 14, 2021

JAK inhibitors such as ruxolitinib (RUX) have proven effective in treating intermediate- or high-risk myelofibrosis (MF), but therapy discontinuations are commonly seen due to development of limiting thrombocytopenia. TGFβ is a cytokine that promotes quiescence in normal but not cancerous hematopoietic stem cells, as well as inhibition of normal megakaryocyte proliferation and decreased production of collagen by mesenchymal stromal cells (MSCs), both of which augment bone marrow fibrosis.

AVID200, a TGFβ1/3 inhibitor, targets TGFβ-mediated responses in multiple cell types involved in MF in that it significantly reduces mitotic activity in MSCs as well as the activity of SMAD2, a TGFβ regulator, and collagen expression. In megakaryocytes, AVID200 increased proliferation and decreased phosphorylated SMAD2 without affecting total SMAD2/3. These findings indicate that TGFβ modulation by AVID200 may fill a treatment gap for patients with MF previously treated with RUX. This phase 1b study enrolled 22 patients with intermediate-2 or high-risk MF and grade 2/3 bone marrow fibrosis (BMF) who were resistant/intolerant to RUX.

At baseline, the JAK2 V617F mutation was detected in 71% of cases. Additional mutations in these patients included TET2 (29%), ASXL1 (24%), and CALR (19%). Median time after RUX discontinuation was 7.4 months (range, 0.5-59.9 months). Twenty-one patients were administered AVID200 intravenously on day 1 of a 21-day cycle. Response was assessed by the International Working Group/European LeukemiaNet criteria after 6 cycles of AVID200. The median number of AVID200 cycles received was 6 (range, 1-17), and 7 patients received >6 cycles. International Working Group-Myeloproliferative Neoplasms Research and Treatment response criteria indicated limited clinical responses at cycle 7 of therapy. Discontinuation of AVID200 was primarily attributed to progressive disease (n = 8) and lack of response (n = 5), as determined by study investigators. Grade 3/4 hematologic and nonhematologic (n = 8) adverse events were observed in 16 (76.2%) patients. Hematologic events were anemia (n = 6) and thrombocytopenia (n = 2). There were 9 nonhematologic events, each being experienced by only 1 patient (epistaxis, mucositis, extraocular muscle paresis, fatigue, rash, duodenal hemorrhage, gastric hemorrhage, urinary tract infection, and syncope).

Median change in total symptom score was –50% (range, –100% to +185.7%) and change in palpable spleen length was +10% (range, –70% to +150%). An increase in platelet counts from baseline during treatment was observed in 9 patients, and 2 patients’ platelet counts were normalized. Maximum changes in platelets from baseline across all cycles was +63.8% (range, –15.7% to +505.5%). In 7 evaluable subjects, median platelet count increased after cycle 6 (215 × 109/L; range, 66-263) compared with baseline (114 × 109/L; range, 28-695). Bone marrow biopsies did not reveal any change in the degree of BMF from baseline but levels of TGFβ1 which were elevated at baseline had decreased 21 days after the last dose of AVID200 in all patients.

In conclusion, AVID200 can improve TGFβ-regulated progression of thrombocytopenia in patients with advanced MF. Since clinical responses at cycle 7 of therapy in this patient population were limited, AVID200 may be more applicable in the context of combination therapy in MF patients with thrombocytopenia mediated by TGFβ.

Source: Mascarenhas J, Kosiorek HE, Bha R, et al. Treatment of myelofibrosis patients with the TGF-β 1/3 inhibitor AVID200 (MPN-RC 118) induces a profound effect on platelet production. American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021. Abstract 142.

Related Articles
Patients with Advanced Myelofibrosis Receiving Bomedemstat Exhibit Improved Clinical Outcomes Compared to JAK Inhibitors
Conference Correspondent
Safe and effective therapeutic options are needed in patients with advanced myelofibrosis and high-risk mutations. Bomedemstat demonstrated improvements in symptoms and spleen responses in patients previously treated with ruxolitinib.
Tagraxofusp Monotherapy Demonstrated Clinical Efficacy in Patients with Advanced Myelofibrosis and Refractory to JAK Inhibitor Therapy
Conference Correspondent
JAK inhibitors are approved in myelofibrosis for relief of symptoms and improvement in spleen responses but have not been shown to impact disease progression. Tagraxofusp monotherapy holds promise for treating myelofibrosis patients who are refractory to JAK inhibitors based on early clinical data.
Association Between IPSS Score and JAK Mutation Characterize Patients with Myelofibrosis at High Risk for Thrombosis
Conference Correspondent
Thrombus formation in patients with myelofibrosis is a common marker of disease progression. The relationship between IPSS score and JAK mutation status may distinguish patients at high risk for thrombosis, which may serve as a guide to therapy decisions.
Last modified: December 14, 2021

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
    Profession or Role
    Primary Specialty or Disease State
  • Please enter your mailing address.

    Address Line 2
    Zip Code